Core Viewpoint - MicroPort Robotics-B experienced a significant stock price increase, with a rise of over 24% in early trading, reaching a peak of 26.48 HKD per share, and maintaining a strong performance at 26.16 HKD per share as of 10:38 AM [1]. Group 1 - The company announced that the cumulative order volume for its core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 230 units [3]. - The commercial orders for the core product, the TUMAI endoscopic surgical robot, have exceeded 160 units globally, with nearly 120 new orders acquired this year [3]. - The company has completed over 150 commercial installations across its various products [3]. Group 2 - The company’s self-developed bronchoscopic surgical robot, the UniPathTM electronic bronchoscopic navigation system, has officially received approval from the National Medical Products Administration [4]. - This approval represents a milestone breakthrough in the field of surgical robotics, indicating a comprehensive coverage of key technological pathways for minimally invasive diagnosis and treatment in domestic surgical robots [4].

Core Viewpoint - Micron Robotics-B (02252) has achieved a significant milestone with the approval of its bronchoscopic surgical robot, UniPathTM, by the National Medical Products Administration (NMPA), marking a breakthrough in the field of surgical robotics and expanding its product offerings to seven approved surgical robots [1] Group 1: Company Developments - The stock price of Micron Robotics-B surged by 13.58% to HKD 24.08, with a trading volume of HKD 109 million [1] - The approval of UniPathTM represents a comprehensive coverage of key technological pathways in minimally invasive diagnosis and treatment for domestic surgical robots [1] - Micron Robotics-B is now the first and only company globally to commercialize products across all five major categories of surgical robots [1] Group 2: Product Details - UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, ultra-thin snake-like robotic catheter to access hard-to-reach narrow lesions through natural body cavities [1] - The platform is significant for the early diagnosis and treatment of early-stage cancers, such as small nodules in the lungs [1]

Core Viewpoint - MicroPort Scientific Corporation's stock (02252) rose over 7% following the announcement of the approval of its bronchoscopic surgical robot, UniPathTM, by the National Medical Products Administration (NMPA) [1] Group 1: Company Developments - The UniPathTM electronic bronchoscopic surgical navigation system has received NMPA approval, marking a significant milestone in the development of surgical robotics [1] - This approval increases the total number of surgical robot products approved for commercialization by the company to seven, making it the first and only company globally to achieve commercialization across all five major categories of surgical robots [1] Group 2: Product Features and Significance - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible and slender snake-like robotic catheter to access hard-to-reach narrow lesions through natural body cavities [1] - This technology is particularly significant for the early diagnosis and treatment of early-stage cancers, such as small nodules in the lungs [1]

Core Insights - MicroPort Robotics-B (02252) has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics and indicating comprehensive coverage of key technologies in minimally invasive diagnosis and treatment for domestic surgical robots [1][2] Group 1: Company Developments - The approval of UniPathTM increases the number of products approved for commercialization in the surgical robot sector to seven, making the company the first and only one globally to achieve commercialization across all five major categories of surgical robots [1] - The company is building a comprehensive ecosystem of domestic surgical robots characterized by systematic innovation and platform capabilities, which is accelerating towards large-scale development [1] Group 2: Industry Impact - The bronchoscopic surgical robot represents a critical technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions," and is one of the fastest-growing smart minimally invasive diagnostic and therapeutic platforms in the respiratory intervention field [2] - UniPathTM integrates key technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing procedures on small lesions in dynamic respiratory conditions, thereby expanding the clinical application boundaries of bronchoscopic interventions [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 自願性公告 獨道電子支氣管鏡手術導航系統 獲得國家藥品監督管理局註冊批准 本公告由上海微創醫療機器人（集團）股份有限公司（「本公司」與其附屬公司合 稱「本集團」）自願作出，以向本公司股東及潛在投資者提供有關本集團的最新 業務進展情況。 本公司董事會（「董事會」）欣然宣佈由本集團自主研發的支氣管鏡手術機器人 獨道®UniPathTM電子支氣管鏡手術導航系統（「獨道」）正式獲得國家藥品監督管 理局（「NMPA」）批准。 對本公司的影響 本次獨道獲得NMPA批准，是本集團引領全球手術機器人領域技術與應用發展 的里程碑式突破，也標誌著國產手術機器人在微無創診療關鍵技術路徑上實 現系統性全覆蓋。至此，本集團在手術機器人領域獲批上市的產品數量增至7 款，成為全球首家、也是目前唯一一家實現手術機器人「五大黃金賽道」全賽道 產品商業化上市的企業。一個由 ...